Background: Safety concerns exist for corneal recipients under immunosuppression.
| INTRODUC TI ON
Technological advances such as the development of alpha-1,3-galactosyltransferase gene knockout pigs, genomewide inactivation of porcine endogenous retrovirus (PERV), and the establishment of successful immunosuppression strategies for nonhuman primates (NHP) have increased the feasibility of xenotransplantation clinical trials. [1] [2] [3] [4] [5] The infection risks related to donor-derived pathogens and hostderived opportunistic pathogens under immunosuppression remain a significant challenge to devising clinical trials in xenotransplantation 6, 7 To date, PERV has been a concern as a donor-derived pathogen in xenotransplantation. Importantly, PERV was not transmitted in numerous studies including clinical trials of islet cells, liver cells, and skin xenotransplantation and NHP studies of corneal xenotransplantation; hence, it is uncertain whether PERV poses any risk. [7] [8] [9] [10] [11] [12] [13] Given that the possibility of transmission is independent of the value of the NHP model, the possibility of the transmission remains to be established. 7, 13 To exclude other potentially transmissible organisms, "designated pathogen-free (DPF)" breeding pigs are used to minimize the risk. 6, 14 Importantly, systemic immunosuppressive therapy may not only increase donor-derived, but also host-derived infections.
We have been investigating the feasibility of corneal xenotransplantation in NHP models since 2009. [3] [4] [5] 15 To minimize the transmissible infection, Seoul National University (SNU) miniature pigs were raised in a DPF environment and maintained with standard operating procedures (SOPs). 16 Donor corneas were prepared using SOPs based on international guidelines. 14, 17 Herein, we report long-term outcomes of reactivation of RhCMV disease, adverse reactions, and general welfare in NHPs treated with different immunosuppressants (corticosteroids, costimulatory blockade, or anti-CD20 antibody [Ab]/tacrolimus combination) after porcine corneal xenotransplantation.
| MATERIAL S AND ME THODS

| Donors and recipients for keratoplasty
All studies carried out in our laboratory adhered to The Association for Corneas were harvested from genetically unmodified, pathogenfree SNU miniature wild-type pigs that had been inbred in the DPF (Tables S1 and S2) 
environment of the Xenotransplantation Research
Center at Seoul National University Hospital. SNU miniature pigs are also free of zoonotic viruses of concern such as PCV, PCMV, and PLHV. 16 Between 2009 and 2018, 49 Chinese rhesus macaques were given pig corneas for penetrating keratoplasty or lamellar keratoplasty. The keratoplasty procedures were previously described.
3,4,15,18,19
| Group analysis depending on immunosuppressants used
Postoperatively, all the recipients received daily topical prednisolone and weekly subconjunctival dexamethasone injection as described in previous studies. 3, 4, 15, 18, 19 The recipients were divided into 4 groups depending on the systemic immunosuppressants used Deerfield, IL, USA). Administration schedules of each immunosuppressant were previously described (Table 1) . 3, 4, 15, 18, 19 In CS group, methylprednisolone (Solumedrol; Pfizer, New York, NY, USA) was intramuscularly injected at an initial dose of 2 mg/kg/ day and tapered over 5 weeks.
Recombinant anti-CD154 Abs (V-regions from mouse 5C8 clone;
C-regions human IgG1k) or anti-CD40 Abs (2C10R4, NIH Nonhuman Primate Reagent Resource) was used in CoB group. 20 In the CoB group, in addition to systemic methylprednisolone, intravenous immunoglobulin (IVIG) 1 g/kg was administered on preoperative day 1 and postoperative day (POD) 14. The CD154 group additionally received 15-19 doses of anti-CD154 Ab intravenously at 20 mg/kg/ day; and the CD40 group, 15 doses of anti-CD40 Ab at 30-50 mg/ kg/day intravenously. 3, 4, 19 In the CA group, 3 different protocols depending on the dose and interval of the anti-CD20 Ab and tacrolimus were executed as follows: (a) Full dosage protocol (n = 7) involved administration of anti-CD20 Ab twice in the first week and thereafter every 8 weeks for 6 months, basiliximab on operation day and POD 4, and tacrolimus twice a day at a dose of 0.05 mg/kg; 19 (b) low dosage protocol (n = 6) involved change in anti-CD20 Ab administration interval from 8 to 12 weeks and reduction in the dosage of tacrolimus to 0.035 mg/kg after 4 weeks of administration at a dose of 0.05 mg/kg; (c) tacrolimus alone protocol (n = 2) involved administration of only tacrolimus twice a day at a dose of 0.05 mg/kg and basiliximab on operation day and POD 4 without administration of anti-CD20 Ab.
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We maintained the immunosuppressant protocols mentioned above for 6 months in all the groups. For NHPs that should be followed up for more than 1 year, the immunosuppressant protocol was maintained. Tacrolimus and anti-CD20 Ab were only temporally stopped when a subject developed pancytopenia. A simian varicella virus (SVV) infection outbreak occurred in the facility when experimentation with lower dosage or tacrolimus only protocols (CA) was underway. This resulted in discontinuation of tacrolimus in infected NHPs during the outbreak. Therefore, we excluded 5 SVV-infected primates from the group analysis mentioned above and reported the incident separately.
| Graft survival
Graft clarity, edema, and neovascularization were evaluated by slitlamp biomicroscopy. Rejection score was graded based on previous study and international consensus.
14,15
| Clinical safety evaluations
| General condition monitoring
NHPs were closely monitored daily, including measurement of body temperature and body weight (BW), and any unusual symptoms and signs were immediately reported.
| Hematological and biochemical tests
In all transplanted groups, complete blood count was analyzed every 2 weeks until 6 months, using an automatic hematological analyzer (ADVIA2120i; SIEMENS Healthcare Diagnostics Inc., Tarrytown, NY, USA). Serum biochemistry and electrolytes were measured using a serum chemistry analyzer (HITACHI7180; Hitachi High-Technologies
Corporation, Tokyo, Japan) and evaluated as previously reported. Tacrolimus was administered intramuscularly twice a day at a dose of 0.05 mg/kg. i Tacrolimus was administered intramuscularly twice a day at a dose of 0.05 mg/kg for 4 wk followed by 0.035 mg/kg. To prevent further viral reactivation after SVV outbreak, tacrolimus was stopped in all subjects from April 27, 2017, to June 21, 2017. j Accidently died due to asphyxia after the sedation. k Died of sepsis due to bowel perforation during blood sampling.
Biochemical and electrolyte tests were performed at 2-week intervals until 1 month in the CS group and 6 months in the other groups.
| Quantitation of Rhesus Cytomegalovirus (RhCMV)
The quantification of RhCMV DNA in plasma was determined by quantitative real-time polymerase chain reaction (PCR) using forward and reverse primers, 5′-ACAGAGGCCAGTGGGATGTC-3′
and 5′-CCCTGATGATGGGCATAGATAAG-3′, and a probe, 5′
FAM-CCAGGCACATTCTCTGGGAGCACAC-3′ TAMRA (Bioneer, Daejeon, South Korea). Their sequences are located in the highly conserved RhCMV 156 region and are specific to RhCMV. The PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) was used for the quantification of the signals. 
| Outbreak of SVV infection and death/ infection rate analysis in the presence of immunosuppressants
Outbreak of SVV infection occurred in the primate facility from NHPs that received corneal transplants, 37 other NHPs were also housed in this facility. Eleven of them were receiving immunosuppressants after transplants of organs other than the cornea, while the remaining 26 did not receive immunosuppressants as they had not received transplants yet. 
| Statistical analyses
| RE SULTS
| General condition monitoring in group analysis
All the 44 NHPs maintained good condition, appetite, and physical activity during the study period except for the early weight loss as follows:
All groups except the CS group showed a tendency to lose weight at 1 month. The CD40 group in particular, showed a significant decrease in BW at 1 month (P = 0.0225, Wilcoxon signed rank test) but recovered at 3 and 6 months ( Figure 1A ). The CD154 group showed a 10% weight loss at 3 months after surgery despite good dietary intakes and good physical activities but recovered after supportive care. The weight change was not statistically significant due to the small number.
Body temperature remained stable except for the decrease at 1 month in CD40 group (P = 0.0140, Wilcoxon signed rank test), but remained within the normal ranges reported in previous reports ( Figure 1B ). 
| Hematological tests
White blood cell (WBC) counts were reduced at 6 months in the CS (P = 0.0156, Wilcoxon signed rank test) and CD154 (P = 0.0190, Wilcoxon signed rank test) groups compared with the preoperative level but remained constant throughout the study period in the CD40 and CA groups (Figure 2A ). Hemoglobin (Hb) level tended to decrease in the CD40 (P = 0.0078) and CA (P = 0.0022, Wilcoxon signed rank test) groups at 1 month; however, the Hb level recovered at 6 months ( Figure 2B ).
| Biochemical tests
Aspartate aminotransferase and ALT levels remained stable over time without significant changes in all groups ( Figure 3A,B) . There was no difference in blood urea nitrogen (BUN) level between groups postoperatively. In the CA group, the BUN level temporarily increased at 3 months (P = 0.0170, Wilcoxon signed rank test) ( Figure 3C ).
Creatinine decreased steadily in the CD40 group (preop vs 6 months; P = 0.0391, Wilcoxon signed rank test) and temporally dropped in the CA group (preop vs 1 months; P = 0.0063, Wilcoxon signed rank test), but the changes were within normal ranges ( Figure 3D ). In all groups, blood glucose level did not change with time ( Figure 3E ).
| Electrolyte tests
There was no difference in mean value for sodium (Na) between the groups. The value for Na decreased at 6 months in CA group (P = 0.0201, Wilcoxon signed rank test) but remained within the normal range ( Figure 4A ). The potassium (K) values of the CA and CD40 group tend to increase outside normal ranges, which did not show any statistically significant changes with time in all groups ( Figure 4B ).
| RhCMV monitoring
Prior to xenotransplantation, all NHPs in the CD154 and CA groups did not show RhCMV DNA copies, while some of the NHPs in the CD40 group showed low levels of RhCMV viremia (<50 copies/mL) or CS groups (<200 copies/mL). The mean value of RhCMV DNA copies was lower than 200 copies/mL in all groups and did not increase over the 6 months of treatment ( Figure 5A ). The preoperative RhCMV Ab titer did not elevate with time in all groups ( Figure 5B ). 
| Outbreak of the simian varicella virus and death/infection rate analysis in the presence of immunosuppressants
| Other systemic complications of immunosuppression excluding SVV
No other systemic complications were found in the CS or CoB group. In the CA group, systemic infection occurred in 3 cases Other than infections, 1 NHP in CA group showed tacrolimusassociated thrombotic microangiopathy. Increased levels of lactate dehydrogenase, bilirubin, and decreased levels of Hb and platelets recovered after cessation of tacrolimus and administration of dalteparin and clopidogrel. These hematologic abnormalities recurred when tacrolimus was re-administered, confirming the diagnosis. The laboratory tests normalized after discontinuation of tacrolimus and re-administration of dalteparin. 25 
| D ISCUSS I ON
Corticosteroid therapy alone is sufficient for xenotransplantation using decellularized cornea, but costimulation blockade or combination of anti-CD20 Ab and tacrolimus is more successful for LKP or PKP using cellular cornea.
3,4,15,18,19 Our study indicates that in corneal xenotransplantation, costimulation blockade-based or anti-CD20 Aband tacrolimus-based immunosuppression is not only effective for graft survival, but also safely tolerated for 6 months in NHPs compared to steroids. One-year systemic monitoring results in 9 NHPs under immunosuppression also showed no statistically significant changes in data of 1 year compared with preoperative level or 6 months ( Figure   S1 ).
Transient weight loss in the CD40 group presumably occurred as a result of physical difficulty with feeding that the NHPs faced due to neck collars applied to prevent them from touching their eyes for the first 2 weeks. After removing the neck collars, the NHPs regained their normal weight. Although not significantly, two NHPs in the CD154 group also showed a weight loss of more than 10% at 3 months. Neither decreased dietary intake nor abnormal laboratory findings were observed. We were advised close monitoring of the NHPs by veterinary physicians. Thereafter, the NHPs gradually recovered body weight without any further problems. Since all the studies were carried out sequentially and not simultaneously, different environment may have affected group-to-group variations.
However, the results did not show clinically significant difference between the groups, as most laboratory test values were within the normal range provided by a previous report. 21 Decrease in WBC counts in the CS and CD154 groups suggests that bone marrow suppression should be carefully monitored in this protocol. Given the wide normal ranges in NHPs, 21 and variable preoperative status in each group, liver and kidney function were tolerably maintained over 6 months in all groups. Although it is nonsignificant, the potassium PERV, our group has previously reported no observed PERV transmissions. 11 We investigated the possibility of reactivation of the RhCMV virus throughout the study because viruses such as CMV, varicellazoster virus (VZV), and herpes simplex virus are known to be reactivated by the use of immunosuppressants. 26, 27 It is clinically translatable because RhCMV is well established as a model for human CMV (HCMV) and the Ab measurement method used is also applicable to humans. 23 Rhesus macaques are a widely used experimental animal species and, RhCMV contains most of the HCMV gene families, thus allowing the study of their role in CMV infection. 28 In our study, RhCMV copies were detected in many NHPs but were much lower than the viral load of 1000-100 000 copies/mL that is detected in active CMV disease. 29 Additionally, no clinically symptomatic RhCMV disease was observed, which may be related to the fact that all our NHPs had RhCMV Abs before transplantation. (b) there is currently no searchable report about reactivation of CMV disease in corneal allotransplant recipients. [32] [33] [34] In high-risk corneal allotransplantation, systemic cyclosporine, tacrolimus, or mycophenolate mofetil can be administered systemically. 35, 36 As far as the authors know, there has been no report of serious pathogen reactivation under immunosuppression from these studies on corneal allotransplantation presumably because most of the studies used one drug (monotherapy). [32] [33] [34] 36, 37 Considering that high dosage of triple combination of immunosuppressants (anti-CD20 antibody, tacrolimus, basiliximab)
is used in corneal xenotransplantation, it would be reasonable to evaluate whether the effect of our triple immunosuppressants regimen on the CMV disease in xenotransplantation is comparable to effect of the other triple immunosuppressants regimen (antithymocyte globulin, tacrolimus with either mycophenolate or azathioprine) 30 CMV viremia (<200 copies/mL) has also been reported in patients with transplantation. 38 There is a need to investigate whether steroids have a role in the resolution of RhCMV infection.
Simian varicella virus (SVV) is closely related to VZV and induces a natural varicella-like disease in nonhuman primates. Disseminated SVV infection in immunocompromised NHPs was associated with a high fatality rate during the outbreak (66.7%). Since this was the first SVV outbreak at our primate center, the diagnosis of the disease was delayed and the first 3 infected NHPs did not receive adequate antiviral treatment, leading to death. Disseminated VZV infection is very rare with a high mortality rate in humans. According to one retrospective study, only 56 renal transplant recipients had a disseminated VZV infection during 26 years, and the mortality rate was 30%. 27 From this event, we learned that antiviral prophylaxis is important even for rare diseases, because of the high fatality rate in immunocompromised conditions. According to our study, other infections associated with immunosuppression seem to be tolerable if they are detected early through close monitoring.
As for bacterial or protozoal infections, we reported a rate of 6.8% among all NHPs under immune suppression therapy throughout the whole trial. However, the infection rate went up to 25% in NHPs under anti-CD 20 Ab/tacrolimus regimen, although the difference was not statistically significant. Our triple immunosuppressant regimen (anti-CD 20 Ab/tacrolimus/basiliximab) showed comparable safety with that described in a previous report, which presented a 27.3% bacterial or protozoal infection rate in patients who received anti-CD20 Ab. 39 An important limitation of this study concerns missing data in the CS or anti-CD 154 groups as we conducted experiments using is not a complete pathogen safety study or an outbreak study.
In conclusion, our study is noteworthy in that we report the long-term safety-related issues for systemic immunosuppression in corneal xenotransplantation. It draws attention to the need for proper monitoring and prophylaxis to reduce infection and immunosuppressant-related adverse reactions in future clinical trials for corneal xenotransplantation.
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